351 related articles for article (PubMed ID: 30195072)
1. Preliminary evaluation of a novel
Zhou D; Xu J; Mpoy C; Chu W; Kim SH; Li H; Rogers BE; Katzenellenbogen JA
Nucl Med Biol; 2018 Nov; 66():26-31. PubMed ID: 30195072
[TBL] [Abstract][Full Text] [Related]
2. Solid phase radiosynthesis of an olaparib derivative using 4-[
Xu J; Chen H; Rogers BE; Katzenellenbogen JA; Zhou D
Nucl Med Biol; 2022; 114-115():65-70. PubMed ID: 36193598
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
[TBL] [Abstract][Full Text] [Related]
4. First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.
Persson M; Liu H; Madsen J; Cheng Z; Kjaer A
Nucl Med Biol; 2013 Jul; 40(5):618-24. PubMed ID: 23602763
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and Evaluation of [
Zheng W; Huang Y; Xie Y; Yang T; Cheng X; Chen H; Li C; Jiang Z; Yu Z; Li Z; Zhang L; Yuan L; Liu Y; Liang Y; Wu Z
Mol Pharm; 2024 May; 21(5):2606-2621. PubMed ID: 38606716
[TBL] [Abstract][Full Text] [Related]
6. Design and Investigation of a [
Yang D; Comeau A; Bowen WD; Mach RH; Ross BD; Hong H; Van Dort ME
Mol Pharm; 2017 Mar; 14(3):770-780. PubMed ID: 28135101
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Biologic Evaluation of a Novel
Donnelly DJ; Smith RA; Morin P; Lipovšek D; Gokemeijer J; Cohen D; Lafont V; Tran T; Cole EL; Wright M; Kim J; Pena A; Kukral D; Dischino DD; Chow P; Gan J; Adelakun O; Wang XT; Cao K; Leung D; Bonacorsi SJ; Hayes W
J Nucl Med; 2018 Mar; 59(3):529-535. PubMed ID: 29025984
[TBL] [Abstract][Full Text] [Related]
8. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer.
Sreekumar S; Zhou D; Mpoy C; Schenk E; Scott J; Arbeit JM; Xu J; Rogers BE
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834491
[TBL] [Abstract][Full Text] [Related]
11. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
12. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of a
Jadvar H; Chen K; Park R; Yap LP; Vorobyova I; Swenson S; Markland FS
Amino Acids; 2019 Nov; 51(10-12):1569-1575. PubMed ID: 31621030
[TBL] [Abstract][Full Text] [Related]
14.
Lee BS; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim MH; Kim MH; Chi DY; Ahn H; Lee YJ; Lee KC; Lim SM
Prostate; 2020 Dec; 80(16):1383-1393. PubMed ID: 32960990
[TBL] [Abstract][Full Text] [Related]
15. An
Zmuda F; Blair A; Liuzzi MC; Malviya G; Chalmers AJ; Lewis D; Sutherland A; Pimlott SL
J Med Chem; 2018 May; 61(9):4103-4114. PubMed ID: 29630818
[TBL] [Abstract][Full Text] [Related]
16. [
Amor-Coarasa A; Kelly J; Ponnala S; Vedvyas Y; Nikolopoulou A; Williams C; Jin MM; David Warren J; Babich JW
Nucl Med Biol; 2018 May; 60():37-44. PubMed ID: 29544122
[TBL] [Abstract][Full Text] [Related]
17. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
[TBL] [Abstract][Full Text] [Related]
18. Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.
Schwarzenböck SM; Schmeja P; Kurth J; Souvatzoglou M; Nawroth R; Treiber U; Kundt G; Berndt S; Graham K; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Dinkelborg L; Wester HJ; Krause BJ
Mol Imaging Biol; 2016 Jun; 18(3):393-401. PubMed ID: 26483088
[TBL] [Abstract][Full Text] [Related]
19. Quantitative PET Imaging of Tissue Factor Expression Using 18F-Labeled Active Site-Inhibited Factor VII.
Nielsen CH; Erlandsson M; Jeppesen TE; Jensen MM; Kristensen LK; Madsen J; Petersen LC; Kjaer A
J Nucl Med; 2016 Jan; 57(1):89-95. PubMed ID: 26383146
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]